This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ASRGL1 / Isoaspartyl peptidase/L-asparaginase · IHC design guide
Design Immunohistochemistry for ASRGL1
Plan paraffin-section ASRGL1 IHC around the cytoplasmic staining seen in seminiferous ducts and female genital tract glandular cells (HPA tissue IHC). This guide covers fixation consistency, controls, and epitope selection for a protein with 2 isoforms and α/β chain processing (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ASRGL1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Predominantly cytoplasmic staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic signal in seminiferous ducts and female genital glands (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A08869-1) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining has medium consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Overexpressed in uterine carcinoma (UniProt) | |
| Isoform / epitope | 2 isoforms; α/β cleavage makes epitope location relevant (UniProt) |
Section 1
Recommended ASRGL1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet: A08869-1) with published chromogenic ASRGL1 protocols for human brain (PMC11099023) and cervical carcinoma tissue (PMC6059725).
| Sample | Paraffin-embedded human brain tissue; fixative not specified (datasheet A08869-1) |
| Fixation | Image fixative and duration unreported (datasheet A08869-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A08869-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A08869-1) |
| Primary antibody | Rabbit anti-ASRGL1, 1:50 recommended; image 2 μg/ml (datasheet A08869-1) |
| Primary incubation | Overnight at 4 °C (datasheet A08869-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A08869-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ASRGL1-positive staining in granular cells - cytoplasm/membrane of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression most abundant in seminiferous ducts and glandular cells of female genital tract. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 for the catalog antibody (datasheet: A08869-1); citrate retrieval was reported with a different antibody (PMC6059725).
Section 2
What Is the Expected ASRGL1 Staining Pattern?
ASRGL1 should stain mainly in the cytoplasm of seminiferous ducts and female genital tract glandular cells (HPA tissue IHC). Cytoplasmic localisation fits a protein with no transmembrane segment (UniProt Q7L266 topology). HPA rates tissue IHC reliability as Enhanced, while reporting only medium consistency between antibody staining and RNA expression (HPA tissue IHC). Interpret each result by cell type and compartment, not overall slide colour.
| Clear cytoplasmic signal in cervical or endometrial glandular cells, or cells of seminiferous ducts. | This fits the reported distribution: female genital tract glandular cells and seminiferous ducts are prominent, with High staining in cervical and endometrial glandular cells (HPA tissue IHC). Compare staining within the relevant cell population, because adjacent cells need not share its intensity. |
| Predominantly nuclear, sharply surface-restricted, or indiscriminate staining across a tissue section. | These are poor matches for the mainly cytoplasmic tissue pattern (HPA tissue IHC; UniProt Q7L266 subcellular location). Cerebellar granular cells are a stated cytoplasm/membrane exception (HPA tissue IHC). Nuclear signal alone is therefore insufficient to call tissue IHC positive; assess morphology and controls. |
| Strong colour in cells listed as Not detected, such as adipocytes or alveolar cells. | HPA reports no detected ASRGL1 staining in those specified cells, not a universal absence from their entire organs (HPA tissue IHC). Consider cross-reactivity or endogenous detection activity, and compare a no-primary control before assigning the colour to ASRGL1 (general IHC practice). |
| Haze across tissue, stroma, and blank areas that obscures cell boundaries. | A widespread background pattern cannot establish the reported cell-specific cytoplasmic localisation (HPA tissue IHC). Check the no-primary control and detection reagents, then reassess blocking and washes (general IHC practice). Score only signal distinguishable from background in identifiable cells. |
| No visible signal in cervical or endometrial glandular cells on an otherwise readable section. | That conflicts with their reported High staining (HPA tissue IHC), but one negative slide does not establish biological absence. Check tissue identity, positive-control performance, antibody dilution, retrieval, and detection steps (general IHC practice); HPA provides no ASRGL1-specific retrieval or fixation response here. |
💡Expected ASRGL1 appearanceCall a positive IHC result when High, predominantly cytoplasmic staining is resolved in cervical or endometrial glandular cells (HPA tissue IHC); broad background or staining confined to unrelated cells is suspect (general IHC practice).
| Tissue and cell selection | Cervical and endometrial glandular cells and cerebellar granular cells are reported High; glial cells in cerebral cortex are Low (HPA tissue IHC). Select and score the named cells, since a weak field elsewhere cannot substitute for a known-positive cell population. |
| Subcellular context | UniProt places ASRGL1 in the cytoplasm and at the sperm-tail midpiece (UniProt Q7L266 subcellular location). HPA describes tissue staining as mainly cytoplasmic, with cytoplasm/membrane staining in cerebellar granular cells (HPA tissue IHC). Neither source makes nuclear-only tissue staining a general expectation. |
| Protein processing and antibody epitope | ASRGL1 autocleaves into alpha residues 1–167 and beta residues 168–308 (UniProt Q7L266 processing). Which chain an antibody detects depends on its epitope; no epitope for the catalog antibody is supplied here. Do not infer chain-specific staining or cleavage-dependent IHC performance. |
| Isoforms | UniProt lists 2 ASRGL1 isoforms (UniProt Q7L266 isoforms). Without an antibody epitope or isoform-specific tissue evidence, the reported IHC distribution cannot be assigned to one isoform. Interpret staining as ASRGL1-associated signal subject to the antibody's documented specificity. |
| Antibody validation and evidence limit | Three listed antibodies have Enhanced IHC validation, including HPA029725, HPA055572, and CAB070192 (HPA antibody records). Enhanced supports the reported pattern through independent antibodies or orthogonal data; HPA still describes medium staining–RNA consistency (HPA tissue IHC). Validation does not establish performance under every local staining condition. |
| IF/ICC Q: Should fluorescence mirror tissue IHC? | A: HPA ICC-IF reports microtubules as the main approved location, with approved nucleoplasm and cytokinetic bridge locations (HPA subcellular). That is cell-image evidence, while this page's expected slide pattern comes from tissue IHC (HPA tissue IHC). Assess IF/ICC using its own guide and controls. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected glandular cytoplasm is blank, but the section has intact morphology. | A missed staining step or unsuitable local conditions can suppress chromogenic signal (general IHC practice); target-specific retrieval and fixation effects are unreported in the supplied sources. | Run a known-positive cervical or endometrial glandular section alongside the sample (HPA tissue IHC). Review antibody dilution, retrieval, detection, and counterstain against the IHC-validated antibody's instructions (general IHC practice). |
| Nuclei dominate the signal in a putative positive tissue. | This differs from the mainly cytoplasmic tissue pattern (HPA tissue IHC). HPA's approved nucleoplasm location comes from ICC-IF and does not, by itself, validate nuclear-dominant tissue IHC (HPA subcellular). | Check the no-primary control, nuclear counterstain, and cell boundaries; then compare with a known-positive cytoplasmic pattern (general IHC practice; HPA tissue IHC). |
| Adipocytes or alveolar cells stain more strongly than the intended positive cells. | Those specific cells are listed as Not detected (HPA tissue IHC). Cross-reactivity or endogenous detection activity is possible, but the image alone cannot distinguish them (general IHC practice). | Inspect a no-primary control and the tissue morphology; repeat with an independently validated antibody if available (general IHC practice; HPA antibody records). |
| Diffuse colour covers both tissue and empty spaces. | The distribution obscures the reported cell-specific cytoplasmic pattern (HPA tissue IHC). Excess detection reagent, insufficient washing, or nonspecific binding can create background (general IHC practice). | Compare no-primary and reagent controls; review blocking, washes, antibody dilution, and detection development before scoring cells (general IHC practice). |
| A low-staining field is mistaken for assay failure. | HPA reports Low staining in cerebral cortical glial cells and some glandular populations, while selected cervical and endometrial glandular cells are High (HPA tissue IHC). Expected intensity depends on the named tissue and cell type. | Identify the scored cell population and include a reported High positive tissue in the same run; compare like cells and compartment-specific signal (HPA tissue IHC; general IHC practice). |
| Cerebellar granular cells show a membrane-associated component. | HPA explicitly records High cytoplasm/membrane staining in those cells, although its overall tissue profile is cytoplasmic (HPA tissue IHC). This observation alone does not prove a membrane-spanning ASRGL1 pool (UniProt Q7L266 topology). | Assess whether cytoplasmic staining is also present, verify granular-cell identity, and compare controls before interpreting the membrane-associated component (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing ASRGL1 staining
A08869-1 · IHCIHC analysis of ASRGL1 using anti-ASRGL1 antibody (A08869-1). ASRGL1 was detected in a paraffin-embedded section of human brain tissue. Heat
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000162174-ASRGL1/tissue/cerebral+cortex#imid_7501448
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000162174-ASRGL1/tissue/colon#imid_7497638
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000162174-ASRGL1/tissue/liver#imid_7497631
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000162174-ASRGL1/tissue/kidney#imid_7497640
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA029725; green = ASRGL1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA029725; green = ASRGL1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ASRGL1 IHC & IF
🧪Run cerebellum first and score granular-cell cytoplasmic staining; HPA rates granular cells High (HPA: cerebellum, granular cells, High). Use adipose tissue as the negative comparator because HPA reports adipocytes as Not detected (HPA: adipose tissue, adipocytes, Not detected); on the cerebellar slide, use cells outside the identified granular-cell population to assess background, without assuming they are validated ASRGL1-negative cells (HPA: cerebellum, granular cells, High).
Positive control tissue: Cerebellum (Granular cells - cytoplasm/membrane, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ASRGL1 in A-431, U-251MG, U2OS, with annotated localisation: Microtubules (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and an isotype-matched nonimmune rabbit IgG control alongside an ASRGL1-knockout biological control where available (selected-SKU IHC caption: rabbit primary antibody; standard IHC practice). Quench endogenous peroxidase before HRP/DAB detection in cerebellum (selected-SKU IHC caption: HRP/DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU paraffin-section caption does not state the fixative (selected-SKU IHC caption: fixative unreported). The caption uses heat retrieval in EDTA, pH 8.0, before staining a human brain paraffin section, but does not establish that retrieval is required for every specimen (selected-SKU IHC caption). The supplied evidence does not establish that frozen sections or IF are easier than this documented paraffin-section IHC workflow; for brain IF, assess tissue autofluorescence with an unstained control (selected-SKU IHC caption: paraffin-section workflow; standard IF practice).
HPA tissue IHC evidence for ASRGL1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Granular cells - cytoplasm/membrane | High | Protein (IHC) | HPA → |
| Cervix | Glandular cells | High | Protein (IHC) | HPA → |
| Endometrium | Glandular cells | High | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Basal cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ASRGL1 IHC Tips
Troubleshoot ASRGL1 staining in paraffin sections using the catalog antibody’s brain IHC example and cell specific expression patterns as reference points.
Which retrieval condition should I try first when ASRGL1 staining is weak?
Start with heat mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A08869-1). The selected brain image used a 10% goat serum block and 2 μg/mL primary antibody overnight at 4°C, providing a useful staining benchmark (datasheet A08869-1). If signal is weak, compare shorter and longer heating on adjacent sections while holding antibody and detection conditions constant, and check for tissue lifting (standard IHC practice). Only after optimizing EDTA retrieval, test another buffer as a documented fallback, comparing signal, morphology and background against the same positive control (standard IHC practice).
How should I investigate fixation related variation in ASRGL1 staining?
The selected paraffin section caption does not state a fixative, so ASRGL1 specific sensitivity to fixation remains unknown (datasheet A08869-1). Record fixative, fixation duration and processing history for each block before comparing staining intensity across specimens (standard IHC practice). If prospective material is available, compare matched samples fixed for 6 and 24 hours in neutral buffered formalin, then process and stain them together as a controlled optimization (standard IHC practice). Use the same EDTA pH 8.0 retrieval and 2 μg/mL primary concentration for that comparison; altered staining alone cannot establish an ASRGL1 specific fixation mechanism (datasheet A08869-1; standard IHC practice).
What staining pattern should I expect in an ASRGL1 positive section?
Expect predominantly cytoplasmic staining when evaluating ASRGL1 chromogenic IHC, because UniProt assigns the protein to the cytoplasm (UniProt Q7L266 subcellular location). HPA reports abundant cytoplasmic expression in seminiferous ducts and glandular cells of the female genital tract, with high staining in cerebellar granular cells (HPA tissue IHC). Evaluate signal within the relevant cells before judging a whole section positive, and compare adjacent sections processed with the same EDTA pH 8.0 retrieval (datasheet A08869-1; standard IHC practice). Microtubule, nucleoplasm and cytokinetic bridge annotations come from subcellular IF evidence; they do not establish the expected resolution or specificity of a DAB section (HPA subcellular; standard IHC practice).
Could ASRGL1 processing or isoforms explain inconsistent staining?
ASRGL1 has 2 annotated isoforms and undergoes autocleavage into residues 1–167 and 168–308 (UniProt Q7L266 isoforms and processing). Its annotated topology has no transmembrane segment, but the supplied evidence does not map the catalog antibody’s epitope (UniProt Q7L266 topology; datasheet A08869-1). Check the antibody’s immunogen or epitope documentation before attributing divergent staining to a particular isoform or processed chain (standard IHC practice). For a suspected epitope problem, stain serial positive control sections with the catalog antibody at 2 μg/mL under identical EDTA pH 8.0 retrieval and compare a separately validated epitope reagent if available (datasheet A08869-1; standard IHC practice).
How can IF help resolve ambiguous ASRGL1 IHC localisation?
Use IF/ICC as a separate localisation check alongside chromogenic IHC, since HPA reports microtubules as the main IF location and also records nucleoplasm and cytokinetic bridge staining (HPA subcellular). In cervix or endometrium, multiplex ASRGL1 with a glandular epithelial cytokeratin marker to establish which cells carry signal (HPA tissue IHC; standard IF practice). Choose a far red ASRGL1 fluorophore and include unstained and single colour controls to assess tissue autofluorescence and spectral bleed through (standard IF practice). Because ASRGL1 has no annotated transmembrane segment and is assigned to the cytoplasm, test gentle permeabilisation, such as 0.1% detergent for 5 minutes, against an unpermeabilised control; optimize this IF condition independently of the paraffin IHC caption (UniProt Q7L266 topology and location; standard IF practice).
How do I distinguish ASRGL1 staining from DAB background?
The selected IHC image used a 10% goat serum block, a peroxidase conjugated secondary antibody and DAB development (datasheet A08869-1). For a background investigation, include a section without primary antibody and apply an endogenous peroxidase block, such as 3% hydrogen peroxide for 10 minutes, as general chromogenic IHC controls (standard IHC practice). Compare background in the no primary section with staining in expected ASRGL1 positive cells rather than treating diffuse brown colour as expression (HPA tissue IHC; standard IHC practice). If background persists, titrate primary concentration below the caption’s 2 μg/mL while keeping retrieval, secondary incubation and DAB development matched across sections (datasheet A08869-1; standard IHC practice).
How should I score ASRGL1 across sections with different cell compositions? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population before scoring: HPA reports high staining in cerebellar granular cells and in glandular cells of cervix and endometrium (HPA tissue IHC). Within that population, record the percentage of cells at intensity grades 0–3 and calculate an H score from 0–300, or report percentage positive cells with a stated threshold (standard IHC scoring practice). Normalize counts to the number of eligible target cells, or express positive cell density per mm² of viable target tissue when cell boundaries are unreliable (standard IHC scoring practice). Keep EDTA pH 8.0 retrieval, DAB development, imaging and scoring thresholds consistent across compared sections (datasheet A08869-1; standard IHC practice).
What findings would make an apparent ASRGL1 positive result suspect?
A convincing result should show signal in the relevant cells and a plausible cytoplasmic pattern, consistent with UniProt localisation and HPA tissue IHC (UniProt Q7L266 subcellular location; HPA tissue IHC). Treat staining confined to cut edges, folds or necrotic regions as suspect, and inspect a no primary control for endogenous peroxidase signal (standard IHC practice). Strong signal limited to an unexpected cell population also deserves review against cell specific reference patterns; HPA’s tissue IHC reliability is Enhanced but has medium consistency with RNA data (HPA tissue IHC). Predominantly nuclear DAB staining should prompt a specificity check, while recognizing that HPA separately reports nucleoplasm staining in IF (HPA subcellular; standard IHC practice).
Boster reagents
Best ASRGL1 / Isoaspartyl peptidase/L-asparaginase IHC Antibodies
A08869-1 has real IHC data from paraffin-embedded human brain (A08869-1 IHC image caption). The catalog lists human, mouse, and rat reactivity, but provides no IF image (A08869-1 catalog: reactivity; IF image alts).
Real IHC data
Anti-ASRGL1 Antibody ®
Cat # A08869-1
A08869-1 is the sole card, and its IHC figure shows staining in a paraffin-embedded human brain section (A08869-1 IHC image caption). The catalog lists IHC as an application and human, mouse, and rat reactivity; it provides no IF figure (A08869-1 catalog: applications, reactivity, IF image alts).
Which to pick: For tissue IHC, choose rabbit polyclonal A08869-1 at 1:50 (A08869-1 catalog: host, dilution_raw, IHC dilution); its figure documents a paraffin-embedded human brain section, with the fixative unreported (A08869-1 IHC image caption). For IF/ICC, A08869-1 has a listed 1:50 IF dilution, but IF/ICC is absent from its applications list and no IF image is provided (A08869-1 catalog: IF dilution, applications, IF image alts). For mouse or rat tissue, A08869-1 lists reactivity with both species, while its IHC figure documents human tissue only (A08869-1 catalog: reactivity; IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q7L266 (ASGL1_HUMAN, Isoaspartyl peptidase/L-asparaginase).
- Human Protein Atlas. ASRGL1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. ASRGL1 subcellular location (ICC-IF): Mainly localized to the microtubules. In addition localized to the nucleoplasm and cytokinetic bridge..
- Human Protein Atlas. ASRGL1 antibody validation summary (3 antibodies).
- TDP-43 proteinopathy in ALS is triggered by loss of ASRGL1 and associated with HML-2 expression. Nature communications 2024 — PMC11099023.
- Deletion of Asrgl1 Leads to Photoreceptor Degeneration in Mice. Frontiers in cell and developmental biology 2021 — PMC8805730.
- RNAi‑mediated downregulation of asparaginase‑like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa. Molecular medicine reports 2018 — PMC6059725.
- A Mouse Model with Ablated Asparaginase and Isoaspartyl Peptidase 1 (Asrgl1) Develops Early Onset Retinal Degeneration (RD) Recapitulating the Human Phenotype. Genes 2022 — PMC9408336.
- PubMed PMID:11984834 — UniProt-cited evidence.
- PubMed PMID:14654938 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ASRGL1 (Isoaspartyl peptidase/L-asparaginase). Expected localisation Predominantly cytoplasmic staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A08869-1). Validated IHC antibody: A08869-1 at 1:50 recommended; image 2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Granular cells - cytoplasm/membrane); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human brain tissue; fixative not specified (datasheet A08869-1); 2. Fixation: Image fixative and duration unreported (datasheet A08869-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A08869-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A08869-1); 8. Primary antibody: Rabbit anti-ASRGL1, 1:50 recommended; image 2 μg/ml (datasheet A08869-1); 9. Primary incubation: Overnight at 4 °C (datasheet A08869-1). Watch for: Fixation: Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining has medium consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms; α/β cleavage makes epitope location relevant (UniProt); Regulation: Overexpressed in uterine carcinoma (UniProt). Evidence: UniProt Q7L266, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the microtubules. In addition localized to the…, Datasheet A08869-1, PMC11099023, PMC6059725. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ASRGL1/immunohistochemistry-ihc-guide.